Claims for Patent: 10,149,893

Summary for Patent: 10,149,893

Title:	Methods for modifying progression of osteoarthritis
Abstract:	Methods for modifying progression of osteoarthritis by local administration of a clostridial derivative, such as a botulinum toxin, to an arthritis-affected site are disclosed herein.
Inventor(s):	Jiang; Guang L. (Irvine, CA), Turkel; Catherine (Newport Coast, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	14/035,622
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,149,893
Patent Claims:	1. A method for modifying the levels and/or activities of at least one agent associated with osteoarthritis-mediated cartilage degradation in a patient in need thereof, the method comprising locally administering a therapeutically effective amount of a botulinum toxin type A to an osteoarthritis-affected site of the patient, thereby mitigating the osteoarthritis-mediated cartilage degradation; wherein the administering is by intra-articular injection; wherein the therapeutically effective amount is greater than 300 units; and wherein the botulinum toxin type A is onabotulinumtoxinA. 2. The method of claim 1, wherein the administering alleviates the pain at the osteoarthritis-affected site of the patient. 3. The method of claim 1, wherein the administering reduces the levels and/or activities of at least one cartilage-degrading agent, increasing the levels and/or activities of at least one cartilage-forming component, or both. 4. The method of claim 1, wherein the therapeutically effective amount is from about 300 units to about 500 units. 5. The method of claim 1, wherein the at least one agent associated with osteoarthritis-mediated cartilage degradation comprises a cartilage-degrading agent, a cartilage-forming component, or mixtures thereof. 6. The method of claim 5, wherein the cartilage-degrading agent is a proteinase. 7. The method of claim 6, wherein the proteinase is selected from the group consisting of metalloproteinases, cysteine proteinases, aspartate proteinases, serine proteinases, and combinations thereof. 8. The method of claim 5, wherein the cartilage-forming component is selected from the group consisting of aggrecan, proteoglycans, collagens, hyaluronan, and combinations thereof. 9. The method of claim 1, wherein the osteoarthritis-affected site is selected from the group consisting of a knee joint, a hip joint, a hand joint, a shoulder joint, an ankle joint, a foot joint, an elbow joint, a wrist joint, a sacroiliac joint, a spine joint, and combinations thereof. 10. A method for alleviating osteoarthritis associated pain in a patient in need thereof, the method comprising locally administering a therapeutically effective amount of a botulinum toxin type A to an osteoarthritis-affected site of the patient; wherein the therapeutically effective amount is greater than 300 units; and wherein the botulinum toxin type A is onabotulinumtoxinA.

Details for Patent 10,149,893

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	December 09, 1991		2039-02-26
Abbvie Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	December 09, 1991		2039-02-26